S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
Log in

NASDAQ:RTRX - Retrophin Stock Price, Forecast & News

$15.49
+0.49 (+3.27 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$14.33
Now: $15.49
$15.56
50-Day Range
$14.40
MA: $16.18
$17.28
52-Week Range
$10.87
Now: $15.49
$24.69
Volume455,900 shs
Average Volume348,460 shs
Market Capitalization$667.87 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$175.34 million
Book Value$5.13 per share

Profitability

Net Income$-102,680,000.00

Miscellaneous

Employees214
Market Cap$667.87 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.


Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) posted its earnings results on Monday, February, 24th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.01. The biopharmaceutical company earned $46.69 million during the quarter, compared to analyst estimates of $46.60 million. Retrophin had a negative net margin of 83.51% and a negative return on equity of 56.87%. The business's revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. View Retrophin's Earnings History.

When is Retrophin's next earnings date?

Retrophin is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Retrophin.

What guidance has Retrophin issued on next quarter's earnings?

Retrophin updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $175-175 million, compared to the consensus revenue estimate of $173.75 million.

What price target have analysts set for RTRX?

8 Wall Street analysts have issued 12-month price objectives for Retrophin's shares. Their forecasts range from $19.00 to $38.00. On average, they expect Retrophin's share price to reach $29.57 in the next year. This suggests a possible upside of 90.9% from the stock's current price. View Analyst Price Targets for Retrophin.

What is the consensus analysts' recommendation for Retrophin?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.

What are Wall Street analysts saying about Retrophin stock?

Here are some recent quotes from research analysts about Retrophin stock:
  • 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (1/1/2020)
  • 2. Nomura analysts commented, "in PKU Declined; Frees up ~$65mn. RTRX has declined the option for CNSA-001 after strategic review—this has freed up $65mn in capital (and potential dilution), which may be used for acquisition of new drugs/targets. Recall, RTRX paid $10mn for an option to acquire CNSA-001 program for $65mn in 20% cash/80% stock (at $21.40/sh), plus $25mn in milestone payments, on Jan 4, 2018. New BD a EU PKAN Launch. Stock: FSGS DUPLEX 1H21E (was 2H20E); IgAN 1H22E due to slower- than-expected trial enrollment, steps to speed study completion in progress. Fosmet P3 in PKAN Top Line 3Q19 – Approval Likely Even if Primary Endpoint Misses Stat. Sig. Pending P3 data, RTRX intends to submit both NDA and MAA in 2020. Sensitized primary ep (PKAN-ADL) vs. prior studies (UPDRS) highlights FDA flexibility and breadth of potential to detect clinical benefit. Mgmt." (8/8/2019)

Has Retrophin been receiving favorable news coverage?

News articles about RTRX stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Retrophin earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Retrophin.

Are investors shorting Retrophin?

Retrophin saw a increase in short interest in February. As of February 14th, there was short interest totalling 4,440,000 shares, an increase of 10.2% from the January 30th total of 4,030,000 shares. Based on an average daily trading volume, of 389,100 shares, the days-to-cover ratio is presently 11.4 days. Approximately 10.8% of the shares of the company are sold short. View Retrophin's Current Options Chain.

Who are some of Retrophin's key competitors?

What other stocks do shareholders of Retrophin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Retrophin investors own include CVS Health (CVS), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), Intercept Pharmaceuticals (ICPT), Novavax (NVAX), Omeros (OMER), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO) and Exelixis (EXEL).

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
  • Dr. William E. Rote, Sr. VP and Head of R&D (Age 56)
  • Dr. Noah L. Rosenberg, Chief Medical Officer (Age 52)
  • Dr. Eric M. Dube Ph.D., Pres, CEO & Director (Age 46)

Who are Retrophin's major shareholders?

Retrophin's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.90%), Perceptive Advisors LLC (6.73%), State Street Corp (4.05%), Bank of America Corp DE (2.94%), Renaissance Technologies LLC (1.90%) and Jacobs Levy Equity Management Inc. (1.45%). Company insiders that own Retrophin stock include Elizabeth E Reed, Eric M Dube, Laura Clague, Neil F Mcfarlane, Noah L Rosenberg, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

Which major investors are selling Retrophin stock?

RTRX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Perceptive Advisors LLC, UBS Group AG, Rafferty Asset Management LLC, Oak Ridge Investments LLC, Cubist Systematic Strategies LLC, Strs Ohio and Altshuler Shaham Ltd. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Eric M Dube, Laura Clague, Neil F Mcfarlane, Noah L Rosenberg, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin.

Which major investors are buying Retrophin stock?

RTRX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Jacobs Levy Equity Management Inc., Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, Prudential Financial Inc., Bank of America Corp DE, Panagora Asset Management Inc. and Oxford Asset Management LLP. View Insider Buying and Selling for Retrophin.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $15.49.

How big of a company is Retrophin?

Retrophin has a market capitalization of $667.87 million and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-102,680,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. Retrophin employs 214 workers across the globe.View Additional Information About Retrophin.

What is Retrophin's official website?

The official website for Retrophin is http://www.retrophin.com/.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (NASDAQ RTRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  390 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  676
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel